Genitourinary Cancers | Clinical

NCCN Guidelines for RCC Add Frontline Lenvatinib/Pembrolizumab as Preferred Treatment Option

April 17, 2021

Recent updates to the National Comprehensive Cancer Network’s guidelines for renal cell carcinoma reflect quick integration of new agents and combination regimens to provide patients with RCC with more treatment options and the most up-to-date options.

Men With High Genetic Risk of Lethal Prostate Cancer May Lower Their Risk With a Healthier Lifestyle

April 10, 2021

According to new research presented during the virtual AACR Annual Meeting 2021, the likelihood of developing metastatic disease or dying of prostate cancer among men with high genetic risk was lowered in men who maintained a healthy lifestyle.

Similar Outcomes of Multiple Hormonal Agents Give Oncologists Novel Treatment Options for Patients With nmCRPC

April 02, 2021

Alicia K. Morgans, MD, MPH, associate professor of Medicine, Feinberg School of Medicine, Northwestern University, reviewed the clinical trial results for multiple hormonal therapies intended to treat prostate cancer. She explained that many of them show similar outcomes.